Advertisement

Topics

Frontline Cabozantinib Plus Nivolumab/Ipilimumab Explored in Phase III RCC Trial

14:02 EDT 2 May 2019 | OncLive

In an effort to improve outcomes for intermediate- or poor-risk patients with renal cell carcinoma, the phase III COSMIC-313 trial is being initiated, which will evaluate cabozantinib (Cabometyx) in combination with nivolumab and ipilimumab in patients with previously untreated advanced disease.

Original Article: Frontline Cabozantinib Plus Nivolumab/Ipilimumab Explored in Phase III RCC Trial

NEXT ARTICLE

More From BioPortfolio on "Frontline Cabozantinib Plus Nivolumab/Ipilimumab Explored in Phase III RCC Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...